A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)
Chenguang Wang, Chaoxin Zhou, Sheng Hou, Wenqiang Fan, Weizhu Qian, Yule Ren, Xiyuan Chen, Chenhong Pan, Qingcheng Guo, Huaizu Guo, Yajun Guo · 2026
Read A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007) by Chenguang Wang, Chaoxin Zhou, Sheng Hou, Wenqiang Fan, Weizhu Qian, Yule Ren, Xiyuan Chen, Chenhong Pan, Qingcheng Guo, Huaizu Guo, Yajun Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13209631.txt.
Description
Chenguang Wang and a team of co-authors set a three arm plan to judge a factory change for a biosimilar drug. Their study, from twenty twenty-six, deals with CMAB007, a China cleared copy of omalizumab. After clearance, its process was tuned: media was honed and one clean step swapped. Yield rose five fold with the same host cell line. Such shifts demand strict proof that quality and care acts hold.
The team set new make, old make, and the origin drug side by side. Key quality traits were tiered by risk, each tier with its own pass marks. Deep lab reads checked shape and build. Readers in drug making get a tiered bridge for post clearance change.
Catalog record
| CREATOR | Chenguang Wang, Chaoxin Zhou, Sheng Hou, Wenqiang Fan, Weizhu Qian, Yule Ren, Xiyuan Chen, Chenhong Pan, Qingcheng Guo, Huaizu Guo, Yajun Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |